A Phase 2, Single-center, Randomised, Double-blind, Placebo-controlled, Cross-over Cold Challenge Study Investigating the Effect of C21 on Cold-induced Vasoconstriction in Subjects With Raynaud's Phenomenon (RP) Secondary to Systemic Sclerosis (SSc)
Latest Information Update: 22 May 2023
At a glance
- Drugs Buloxibutid (Primary)
- Indications Raynaud's disease; Systemic scleroderma
- Focus Therapeutic Use
- Sponsors Vicore Pharma
Most Recent Events
- 27 Jul 2022 Results assessing the effects of the angiotensin II type 2 receptor agonist C21 in systemic sclerosis-related Raynaud's published in the Rheumatology
- 22 Dec 2020 Status changed from recruiting to completed.
- 17 Nov 2020 Planned End Date changed from 30 Nov 2020 to 30 Dec 2020.